SOURCE: BioMedReports

BioMedReports

September 21, 2011 07:01 ET

Several Market Factors Should Accelerate the Ascent of Catasys Inc.

LOS ANGELES, CA--(Marketwire - Sep 21, 2011) - A combination of positive pending catalysts combined with the realization of certain milestones should help accelerate the anticipated ascent of Catasys, Inc. (PINKSHEETS: CATSD).

After some key announcements during a presentation at last week's Rodman & Renshaw Healthcare Conference in New York City, investors are watching the stock for new contractual activity and other anticipated initiatives which should begin to facilitate the realization of profits and turn the company's financial fortunes around. Earlier this month, the Company's Board of Directors declared a reverse stock split as part of the Company's initiatives to improve its capital markets appeal to investors.

As BioMedReports first reported earlier in the week, Catasys had found it incredibly difficult to get off the starting block with previous versions of their medical treatment approach which was designed specifically to help healthcare plan providers save money. After some adjustments, proven performance models have now emerged. It appears that the firm is finally beginning to convince the insurance industry that it can help solve a $21 billion problem posed by health plan members who suffer from substance abuse. Those substance dependent members cost health plans up to eight times more than other enrolled members.

Many of those costs are passed on and have caused insurance premiums to skyrocket 100% during the last 10 years. Because insurance providers are under increasing pressure to reduce costs and legislative Health Care Reform is pressuring the industry for additional price controls, Catasys executives are anticipating that additional clients will engage them and contract their unique service.

It appears that the firm's revised business model has finally put them on track to realize their long promised potential and since their patented, proprietary technology is now the only solution with proven efficacy in this space, Catasys should be primed for rapid growth and expansion.

We fully anticipate that Catasys will reach their recently stated profitability goals. In addition, the on-going development of existing client relationships coupled with a strong sales pipeline should facilitate exponential revenue growth during 2012 and beyond.

News announcements should call more investor attention to Catasys as it attains some of their anticipated milestones in the days and weeks ahead; particularly since the current market valuation does not yet reflect these pending developments.

A full exclusive report about Catasys, including details about the company's revenue model and latest investor presentation is available now at:

http://biomedreports.com/2011092177973/several-market-factors-should-accelerate-the-ascent-of-catasys-inc.html

In addition, investors interested in accessing BioMedReports' new complete FDA Calendar and database of clinical trials and world-wide regulatory decisions which can be used to make more profitable trades during today's volatile markets can go to:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556